Atlas Trials

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Clinical trial NCT05596409 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05596409
Sponsor
Stemline Therapeutics, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2023-05-19
Primary completion
2026-11-01
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.